Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 447-453

  Jerling, Markus ^a   Merlé, Yann ^b   Mentré, France ^b   Mallet, Alain ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Clozsapine

Indexed keywords

CLOZAPINE;

ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 0030721713     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00606.x     Document Type: Article

References (39)

1. Lieberman JA, Alvir JM. A report of clozapine-induced agranulocytosis in the United States. Drug Safety 1992; 7(suppl 1): 1-2.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double blind comparison versus chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
3. Gauch R, Michaelis W. The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo-[b,c][1, 4] diazepine(clozapine) in mice, dogs and human subjects. Farmaco 1971; 26: 667-681.
4. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl) 1989; 99 Suppl: S32-S37.
5. Rosenthaler J, Nimmerfall F, Sigrist R, Munzer H. Nonequilibrium method for the radioimmunoassay of clozapine in the presence of metabolites. Eur J Biochem 1977; 80: 603-609.
6. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-374.
7. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
8. Dahl ML, LLerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-74.
9. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
10. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
11. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
12. Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4: 402-405.
13. Cheng WS, Murphy TL, Smith MT, Cooksley WG, Halliday JW, Powell LW. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47: 516-524.
14. Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988; 34: 445-449.
15. Choc MG, Hsuan F, Honigfeld G, et al. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7: 347-351.
16. nd ed, London: Lea and Febiger, 1989: 376.
17. Bondesson U, Lindström LH. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 1988; 95: 472-475.
18. Jerling M, Merlé Y, Mentré F, Mallet A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant therapy with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994; 38: 453-462.
19. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 3: 645-656.
20. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
21. Parzen E. On estimation of probability density function and mode. O.N.R. Technical Report 1961; 40.
22. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1 A2 activities. Clin Pharmacol Ther 1992; 52: 643-658.
23. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602.
24. Lin SK, Chang WH, Chung MC, Lam YW, Jann MW. Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 1994; 34: 318-324.
25. Haring C, Barnas C, Saria A, Humpel C, Fleischhacker WW. Dose-related plasma levels of clozapine, letter. J Clin Psychopharmacol 1989; 9: 71-72.
26. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989; 99 Suppl: S38-S40.
27. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine :letter:. Pharm Res 1994; 11: 1221.
28. Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21-22.
29. Raitasuo V, Lehtovaara R, Nuttunen MO. Carbamazepine and plasma levels of clozapine :letter:. Am J Psychiatry 1993; 150: 169.
30. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 23-25.
31. Kalow W. Variability of caffeine metabolism in humans. Arzneimittelforschung 1985; 35: 319-324.
32. Shaw-Stiffel TA, Tang BK, Spielberg SP, Shear NH. Caffeine - a novel probe to assess drug effects on hepatic cytochrome P-450 activity [Abstract]. Hepatology 1988; 8: 1385.
33. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
34. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critial appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
35. Ackenheil M. Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl) 1989; 99 Suppl: S32-S37.
36. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235.
37. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13: 383-390.
38. Gunther W, Baghai T, Naber D, et al. EEG alterations and seizures during treatment with clozapine. A retrospective study of 2843 patients. Pharmacopsychiatry 1993; 26: 69-74.
39. Freeman DJ, Oyewumi K. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997; 32: 93-100.